2
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Platelet-Surface Interaction: Effects of Dextran 70 on Platelet Retention in Extracorporeal Surfaces

&
Pages 489-502 | Received 24 Jan 1975, Published online: 11 Jul 2009

References

  • Abildgaard V., Skjorten F. “Influence of LMWD and Thrombin Infusions on Blood Platelets and Fibrinogen,”. J. Atheroscler. Res. 1968; 8: 69–76
  • Andrade J. D., Kunitomo K., Van Wagenen R., Kastigir B., Gough D., Kolff W. J. “Coated Adsorbents for Direct Blood Perfusion: HEMA/Activated Carbon I,”. Trans. Amer. Soc. Art. Intern. Org. 1971; 17: 222
  • Andrade J. D., Van Wagenen R., Chen C., Ghavamian M., Volder J., Kirkham R., Kolff W. J. “Coated Adsorbents for Direct Blood Perfusion II,”. Ibid. 1972; 18: 473
  • Arfors K. E. “Drugs, Platelets, and Injury to Microcirculation,”. Can. Med. Assoc. J. 1973; 108: 456
  • Arturson G., Granath K., Thoren L., Wallenius G. “The Renal Excretion of Low Molecular Weight Dextran,”. Acta Chir. Scand. 1964; 127: 543–551
  • Atik M. “The Uses of Dextran in Surgery: A Current Evaluation,”. Surgery 1969; 65: 548–562
  • Aviram A., Keynan A., Czaczkes J. W. “Reduction of Shunt Clotting by Low Molecular Weight Dextran,”. Excerpta Med. Int. Congr. Ser. 1969; 179: 46–49
  • Brewer S. S. “Stenoplastic Effect of Dextran on Platelets. The Mechanism for Prevention of Thromboembolism,”. Blood 1965; 25: 601–602
  • Thrombotic Diseases with Reference to the Use of Dextrans. Pharmacia AB Symposium, Uppsala, 1967, S. Bygdeman. 1968; 387, Acta Chir. Scand. Suppl
  • Bygdeman S. “Prevention and Therapy of Thromboenbolic Complications with Dextran,”. Progr. Surg. (Basel) 1969; 7: 114–139
  • Bygdeman S., Eliasson R. “Effect of Dextrans on Platelet Adhesiveness and Aggregation,”. Scand. J. Chin. Invest. 1967; 20: 17–23
  • Bygdeman S., Johnsen O. “Effect of Dextrans on Platelet Function,”. Acta Med. Scand. Suppl. 1971; 525: 249–252
  • Carey J. S. “Colloids and Crystalloids for Volume Replacement During and After Surgery,”. Hemodilution. Theoretical Basis and Clinical Application. Karger, Basel 1972; 229–246
  • Chang T. M. S. “Semipermeable Microcapsules,”. Science 1964; 146: 524–525
  • Chang T. M. S. “Semipermeable Aqueous Microcapsules (‘Artificial Cells’): With Emphasis on Experiments in an Extracorporeal Shunt System,”. Trans. Amer. Soc. Art. Intern. Org. 1966; 12: 13–19
  • Chang T. M. S. “Removal of Endogenous and Exogenous Toxins by a Microencapsulated Adsorbent,”. Can. J. Physiol. Pharmacol. 1969; 47: 1043–1045
  • Chang T. M. S. Artificial Cells. Thomas, Springfield, Illinois 1972
  • Chang T. M. S. “Hemoperfusions over Microencapsulated Adsorbent in a Patient with Hepatic Coma,”. Lancet 1972; ii: 1371–1372
  • Chang T. M. S. “Platelet-Interaction with Albumin-coated Surfaces,”. Can. J. Physiol. Pharmacol. 1974; 52: 275–285
  • Chang T. M. S. “Microencapsulated Adsorbent Hemoperfusion for Uremia, Intoxication, and Hepatic Failure,”. Kidney Int. 1975; 7: S787–S792
  • Chang T. M. S., Coffey J. F., Barre P., Gonda A., Dirks J. H., Levy M., Lister C. “Microcapsule Artificial Kidney: Treatment of Patients with Acute Drug Intoxication,”. Can. J. Med. Assoc. February 1973; 108: 429–433
  • Chang T. M. S., Gonda A., Dirks J. H., Malave N. “Clinical Evaluation of Chronic Intermittent or Short Term Hemoperfusions in Patients with Chronic Renal Failure Using Semipermeable Microcapsules (Artificial Cells) Formed from Membrane Coated Activated Charcoal,”. Trans. Amer. Soc. Art. Int. Org. 1971; 17: 246–252
  • Chang T. M. S., Chirito E., Barre B., Cole C., Hewish M. “Clinical Performance Characteristics of a New Combined System for Simultaneous Hemoperfusion-Hemodialysis-Ultrafiltration in Series,”. Ibid. 1975; 21: 502–508
  • Chang T. M. S., Johnson L. J., Ransome O. “Semipermeable Aqueous Microcapsules. Nonthrombogenic Microcapsules with Heparin-Complexed Membranes,”. Can. J. Physiol. Pharmacol. 1967; 45: 705–715
  • Chang T. M. S., Pont A., Johnson L. J., Malave N. “Response to Intermittent Extracorporeal Perfusion through Shunts Containing Semipermeable Microcapsules,”. Trans. Amer. Soc. Art. Intern. Org. 1968; 15: 163–168
  • De Laval M., Hill J. D., Mielke H., Bramson M. L., Smith C., Gerkode F. “Platelet Kinetics during Extracorporeal Circulation,”. Ibid. 1972; 18: 355–357
  • Ewald R. A., Eichelberger J. W., Yound A. A., Weiss H. J., Crosby W. H. “The Effect of Dextran on Platelet Factor 3 Activity: In-vitro and in-vivo,”. Transfusion 1965; 5: 109–119
  • Gruber U. F. Blood Replacement. Springer/Berlin 1969; 55–104
  • Hammarsten J. F., Hellen B. I., Ebert R. V. “The Effects of Dextran in Normovolemic and Oligemic Subjects,”. J. Clin. Invest. 1953; 32: 340–344
  • Hellem A. J. “The Adhesiveness of Human Blood Platelets in-vitro,”. Scand. J. Clin. Lab. Invest. 1960; 12(Suppl. 51)1–117
  • Mainardi L. C., Blanganada K., Mack J. O., Lillehei C. W. “Hemodilution in Extracorporeal Circulation: Comparative Study of Low Molecular Weight Dextran and 5 Percent Dextrose,”. Surgery 1964; 56: 349–354
  • Matheson N. A. “Dextran 40 and Kidney Function,”. Acta Anaesth. Belg. 1968; 19: 165–178
  • Metcalfe W., Rousselot L. M. “A Simple, Accurate, and Rapid Determination of Dextran in Blood and Urine,”. J. Lab. Clin. Med. 1952; 40: 901–906
  • Moncrief J. A., Darin J. C., Canizaro P. C., Sawyer R. B. “Use of Dextran to Prevent Arterial and Venous Thrombosis,”. Ann. Surg. 1963; 158: 553–559
  • Packham M. A., Nishizawa E. E., Mustard J. F. “Effect of Plasma Proteins on Interaction of Platelets with Glass Surfaces,”. J. Lab. Clin. Med. 1969; 73: 686–697
  • Ricketts C. R. “Interaction of Dextran and Fibrinogen,”. Nature (London) 1952; 169: 970
  • Rieger A. “Blood Volume and Plasma Protein III. Changes in Blood Volume and Plasma Proteins after Bleeding and Immediate Substitution with Macrodex, Rhemomacrodex, and Physiogel in Splenectomized Dog,”. Acta Chir. Scand. 1967; Suppl. 379
  • Ross S. W., Ebert R. V. “Microelectrophoresis of Blood Platelets and Effects of Dextran,”. J. Clin. Invest. 1959; 38: 115–160
  • Rothman S., Adelson E., Schwebel A., Langdell R. D. “Adsorption of C14 Dextran to Human Blood Platelets and Red Cell in-vitro,”. Vox Sang. 1957; 2: 104–109
  • Salzman E. W. “Measurement of Platelet Adhesiveness,”. J. Lab. Clin. Med. 1963; 62: 724
  • Salzman E. W. “Blood Platelets and Extracorporeal Circulation,”. Transfusion 1964; 3: 274–277
  • Schaer H., Kundert H.-P., Hossli G. “Blood Volume Plasma Volume, and Total Plasma Albumin after Substitution of Blood Loss with Physiogel, Macrodex 6%, and 1–8% Ringer-Lactate in Humans,”. Ergeb. Bluttransfus. 1971; 11: 329–343
  • Semple R. E. “Effect of Small Infusions of Various Dextran Solutions in Normal Animals,”. Amer. J. Physiol. 1954; 176: 113–119
  • Sunada T. “Hemorrhagic Disorders in Extracorporeal Circulation,”. Bull. Soc. Int. Chir. 1969; 28: 308–314
  • Watson W. J. “The Effects of Dextran Infusion on Platelet Retention in Extracorporeal Shunts Containing Semipermeable Microcapsules,”. M.Sc. Thesis, Department of Physiology, McGill University. 1973
  • Weiss H. J. “Effect of Clinical Dextran on Platelet Aggregation, Adhesion, ADP Release in man-in-vivo and in-vitro Studies,”. J. Lab. Clin. Med. 1967; 69: 37–46
  • Weiss H. J. “The Pharmacology of Platelet Inhibition,”. Progress in Hemostasis and Thrombosis, T H Spaet. Grune and Stratton, New York 1972; 199–231

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.